Aura Biosciences (AURA) financial statements
Net income was -$106M.
Free cash flow was -$85M.
The diluted share count rose 16332% over the period (dilution).
Income statement
Fiscal years, from Aura Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $18M | $25M | $42M | $65M | $73M | $90M |
| Selling, general and admin | $4M | $10M | $18M | $20M | $23M | $22M |
| Operating income | -$22M | -$35M | -$60M | -$85M | -$96M | -$113M |
| Pre-tax income | — | — | -$59M | -$76M | -$87M | -$106M |
| Income tax | $0 | $0 | $0 | $137,000 | $112,000 | $108,000 |
| Net income | -$22M | -$35M | -$59M | -$76M | -$87M | -$106M |
| EPS (diluted) | -$82.06 | -$8.95 | -$1.96 | -$1.93 | -$1.75 | -$1.76 |
| Diluted shares | 0M | 5M | 30M | 40M | 50M | 60M |
Balance sheet
Fiscal years, from Aura Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $17M | $149M | $189M | $41M | $32M | $144M |
| Total current assets | $18M | $154M | $197M | $232M | $161M | $150M |
| Property, plant and equipment | $4M | $5M | $5M | $3M | $3M | $3M |
| Total assets | $22M | $160M | $224M | $255M | $183M | $169M |
| Total current liabilities | $3M | $7M | $10M | $12M | $15M | $18M |
| Total liabilities | $3M | $8M | $28M | $29M | $31M | $33M |
| Shareholders' equity | -$109M | $152M | $196M | $226M | $152M | $137M |
| Net debt | -$17M | -$149M | -$122M | -$41M | -$32M | -$60M |
Cash flow
Fiscal years, from Aura Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$24M | -$32M | -$55M | -$64M | -$80M | -$85M |
| Capital spending | $771,000 | $2M | $1M | $709,000 | $1M | $447,000 |
| Free cash flow | -$25M | -$35M | -$56M | -$65M | -$81M | -$85M |
| Stock-based compensation | $736,000 | $2M | $6M | $9M | $12M | $14M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AURA.
Open AURA in InvestinglyQuestions
How much free cash flow does Aura Biosciences generate?
-$85M in fiscal 2025 (operating cash flow minus capital spending).
From Aura Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.